Country: United States
Language: English
Source: NLM (National Library of Medicine)
GLIPIZIDE (UNII: X7WDT95N5C) (GLIPIZIDE - UNII:X7WDT95N5C)
Northwind Pharmaceuticals, LLC
GLIPIZIDE
GLIPIZIDE 10 mg
ORAL
PRESCRIPTION DRUG
Glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glipizide tablets are contraindicated in patients with: 1. Known hypersensitivity to the drug. 2. Type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.
Glipizide tablets USP, 10 mg are white, scored, round tablets debossed with Watson 461 and are available in bottles of 30 (NDC 51655-810-52), 60 (NDC 51655-810-25) and 90 (NDC 51655-810-26). Store below 30°C (86°F). Dispense in a tight container as defined in the USP. Keep this and all medication out of the reach of children. Manufactured In India By: Watson Pharma Private Limited Verna, Salcette Goa 403 722 INDIA Manufactured For: Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054 Rev. B 3/2021
Abbreviated New Drug Application
GLIPIZIDE- GLIPIZIDE TABLET NORTHWIND PHARMACEUTICALS, LLC ---------- GLIPIZIDETABLETS, USP FOR ORAL USE RX ONLY DESCRIPTION Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class. The Chemical Abstracts name of glipizide is 1-cyclohexyl-3-[[p-[2-(5-methylpyrazine- carboxamido) ethyl]phenyl]sulfonyl]urea. The molecular formula is C H N O S; the molecular weight is 445.55; the structural formula is shown below: Glipizide, USP is a whitish, odorless powder with a pKa of 5.9. It is insoluble in water and alcohols, but soluble in 0.1 _N_NaOH; it is freely soluble in dimethylformamide. Each tablet, for oral administration, contains 5 mg or 10 mg glipizide, USP. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide; croscarmellose sodium; lactose anhydrous; microcrystalline cellulose; pregelatinized starch 1500 (maize) and stearic acid. CLINICAL PHARMACOLOGY MECHANISM OF ACTION: The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans, glipizide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which glipizide lowers blood glucose during long-term administration has not been clearly established. In man, stimulation of insulin secretion by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment. The insulinotropic response to a meal occurs within 30 minutes after an oral dose of glipizide in diabetic patients, but elevated insulin levels do not persist beyond the time of the meal challenge. 21 27 5 4 Extrapancreatic effects may play a part in Read the complete document